Notice: ASA extends its thoughts and condolences to those affected by the disaster in Oklahoma. Donations to help aid this relief can be made through the American Red Cross website.

>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS
>

FDA MEDWATCH ALERTS

RSS

May 20, 2013

All Sterile Drug Products Made and Distributed By NuVision Pharmacy Dallas Facility: Recall - Lack Of Sterility Assurance

Summary:

All Sterile Drug Products Made and Distributed By NuVision Pharmacy Dallas Facility

May 14, 2013

Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses

Summary:

Zolpidem Containing Products Drug Safety Communication

May 09, 2013

The Compounding Shop: FDA News Release - Lack of Sterility Assurance of Drug Products

Summary:

The Compounding Shop FDA News Release Lack of Sterility

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-13CE

... Read more »

Single Copies, Member Price: $360

ASA Renews Request for Action from OIG on “Company Model”

Wednesday, June 16, 2010

ASA has submitted a letter to the Office of Inspector General (OIG) renewing its March 19, 2009, request for a Special Advisory Bulletin regarding the “company model.” A recent independent legal analysis published in the CCH Health Care Compliance Letter (reprinted with permission) supports ASA’s position that the “company model” potentially violates the Federal anti-kickback and self-referral provisions of the Social Security Act.

OIG "Company Model" Letter - June 16, 2010

« Back to Washington Alerts